Funds and ETFs bioMérieux

Equities

BIM

FR0013280286

Medical Equipment, Supplies & Distribution

Real-time Euronext Paris 12:35:08 2024-03-28 pm EDT 5-day change 1st Jan Change
102.2 EUR +1.04% Intraday chart for bioMérieux +2.05% +1.64%

ETFs positioned on bioMérieux

Name Weight AuM 1st Jan change Investor Rating
0.97% 17 M€ -0.46%
0.26% 1,178 M€ +2.12%
0.24% 5 M€ +4.56%
0.17% 18 M€ +6.77% -
0.14% 5 M€ +10.09% -
0.14% 14 M€ +5.66% -
0.06% 6 M€ -.--% -
0.05% 3,859 M€ +7.97%
0.05% 469 M€ -2.05%
0.05% 6 M€ -.--%
0.03% 30 M€ +5.59% -
0.03% 276 M€ +11.40% -
0.02% 10 M€ -3.35% -
0.02% 205 M€ -.--%
0.01% 284 M€ -.--%
0.01% 7 M€ +2.66% -
0.01% 786 M€ -.--%
0.01% 23 M€ -.--% -
0.01% 274 M€ +15.20%
0.01% 1,166 M€ +0.26% -
0.01% 607 M€ +0.05% -
0.01% 367 M€ +8.59% -
0.00% 31 M€ +8.30% -
0.00% 286 M€ +6.29% -
0.00% 38 M€ +6.05% -
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.7%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.3%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (31.3%), North America (45.4%), Asia/Pacific (17.4%) and Latin America (5.9%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
102.2 EUR
Average target price
110.6 EUR
Spread / Average Target
+8.22%
Consensus